Testing SNA028 for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This early-stage trial tests a new radioactive medicine called SNA028 for patients with advanced colorectal cancer that has returned or grown despite prior treatment. The medicine is designed to target cancer cells that have a specific marker called GPA33.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Advanced colorectal cancer diagnosed by biopsy, with cancer that has grown or returned after standard treatment
- At least one measurable tumor on imaging scans
- Good overall health status (ECOG score 0–1, meaning you can do light activities or are fully active)
- Life expectancy greater than 6 months
- Blood counts, liver, kidney, and clotting function within safe ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new imaging method using a special tracer (GPA33) to find tumors in people with colorectal, gastric, or pancreatic cancer. It may help doctors see tumors more clearly during a PET scan.
This trial tests a new radioactive drug (177Lu-NNS309) for people with advanced pancreatic, lung, breast, or colorectal cancer that has not responded to prior treatments. It aims to see if the drug can target and shrink tumors.
This early-phase study tests two new radioactive treatments (lutetium-177 and actinium-225) together with a guided imaging agent in people with GRPR-positive solid tumors (including prostate, breast, or colorectal cancers). The goal is to see if these treatments can shrink tumors that have stopped responding to standard therapies.
This trial tests a new drug called CC-3, which is a type of antibody designed to help your immune system attack colorectal cancer cells. It is for people whose cancer has spread and who have already tried several standard treatments.
This trial tests a new drug called MRG007 combined with other treatments for people with advanced colorectal cancer that cannot be removed by surgery or has spread. It aims to see if the combination is safe and effective.
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.